In mAb therapy for solid tumors, trastuzumab and pertuzumab were approved by the FDA for human epidermal growth factor receptor 2 (HER2)-overexpressed breast cancer in 1998 and 2012, respectively [3]. This evidence concerns the gene ERBB2 and breast carcinoma.